Haoyuan Pharmaceutical disclosed the 2022 semi -annual report to achieve revenue of 621 million yuan

On August 25, Hao Yuan Pharmaceutical (Code: 688131.SH) released the 2022 semi -annual performance report.

From January 1, 2022-June 30, 2022, the company realized operating income of 621 million yuan, an increase of 36.52%year-on-year, and net profit was 116 million yuan, an increase of 22.51%year-on-year, and the basic earnings per share were 1.12 yuan.

The company's industry serves medical care.

During the company's reporting period, the total assets at the end of the period were 2.625 billion yuan, operating profit was 124 million yuan, accounts receivable was 328 million yuan, and the net cash flow generated by operating activities was -119 million yuan.Cash is 481 million yuan.

Haoyuan Pharmaceutical, the company's full name Shanghai Haoyuan Pharmaceutical Co., Ltd., was established on September 30, 2006. The current general manager Zheng Baofu.Small molecular drugs, the process of research and development and production technology of the intermediate.

- END -